Business Context and Reporting Period
This Form 8-K filing by Nephros, Inc. (NEPH) reports on the results of the 2023 Annual Meeting of Stockholders held on June 1, 2023. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes rather than financial performance.
Material Changes and Voting Results
Stockholders voted on three primary matters at the Annual Meeting:
- Election of Directors: Joseph Harris was elected to the Board of Directors for a three-year term expiring in 2026.
- For: 5,333,628
- Withheld: 867,787
- Broker Non-Votes: 2,430,993
- Ratification of Auditors: Stockholders ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- For: 8,622,127
- Against: 9,252
- Abstain: 1,029
- Broker Non-Votes: 0
- Executive Compensation: Stockholders approved the compensation of named executive officers on an advisory (non-binding) basis.
- For: 5,309,669
- Against: 885,868
- Abstain: 5,878
- Broker Non-Votes: 2,430,993
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Joseph Harris has been elected to the Board of Directors.
- Baker Tilly US, LLP is the confirmed independent auditor for the 2023 fiscal year.
- Executive compensation was approved by a majority of votes cast, though a significant number of shares were withheld or represented as broker non-votes.
- Broker non-votes were significant for the director election and executive compensation proposals (2,430,993 shares each).